@misc{Glazman-Kuśnierczyk_Halina_Interleukin-2_1996,
 author={Glazman-Kuśnierczyk, Halina and Pajtasz-Piasecka, Elżbieta and Radzikowski, Czesław},
 volume={35},
 number={4},
 copyright={Creative Commons Attribution BY-SA 4.0 license},
 journal={Biotechnologia, vol.35, 4 (1996)-.},
 howpublished={online},
 year={1996},
 publisher={Committee on Biotechnology PAS},
 publisher={Institute of Bioorganic Chemistry PAS},
 language={pol},
 abstract={terleukin 2 cDNA (X63-mIL-2) were used as the slow-release system of IL-2 for immunotherapyand chemoimmunotherapy in mice challenged with subcutaneous injections of different non-related tumors (MCA induced fibrosarcomas BFSl and F-69-3, colon carcinoma C38). The combination of one dose of the cytostatic agent (bromoanalog of ifosfamide) administration withsubsequent peritumoral injections of the cytokine-producing cells was observed to be more efficient in the tumor growth inhibition as compared with the cytostatic alone.},
 title={Interleukin-2 Gene Therapy Potentiates the Antitumor Effect of Cytostatic Agent in Mice with Advanced Transplantable Tumors},
 type={Text},
 URL={http://rcin.org.pl/Content/146555/PDF/POZN271_182221_biotechnologia-1996-no4-glazman.pdf},
 keywords={biotechnology},
}